Cellectis Presents Updated Clinical and Translational Data :

NEW YORK, June 09, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company...

Related Keywords

New York , United States , Paris , France General , France , North Carolina , Raleigh , American , Pascalyne Wilson , Ashleyr Robinson , Nicolas Boissel , Arthur Stril , American Society Of Hematology , Securities Exchange Commission , Nasdaq , Cellectis The Company Euronext Growth , European Hematology Association , Euronext Growth , Hematology Adolescent , Young Adult Unit , Intermediate Dose Level , American Society , Dose Level , Nasdaq Global Market , Private Securities Litigation Reform Act , Annual Report , Chief Business Officer , Lifesci Advisors , Paris Stock Exchange Alcls , Ellectis Inc , Allogeneic , Biotech , Iopharma , Ar T ,